Isofol Medical
Clinical-stage biotech developing a folate-based therapy to enhance cancer treatments.
ISOFOL | ST
Overview
Corporate Details
- ISIN(s):
- SE0009581051
- LEI:
- 549300MCXYAHG7VBHX75
- Country:
- Sweden
- Address:
- C/O Biotech Center, Arvid Wallgrens, 413 46 Göteborg
- Website:
- https://isofolmedical.com/
Description
Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-07-16 11:07 |
Isofol announces new preclinical data supporting the previously communicated cl…
|
English | 69.3 KB | ||
| 2024-07-16 11:07 |
Isofol meddelar att nya prekliniska data stöder den tidigare annonserade klinis…
|
Swedish | 71.5 KB | ||
| 2024-07-05 10:15 |
Isofol announces a post hoc per-protocol analysis of the AGENT study, further s…
|
English | 78.2 KB | ||
| 2024-07-05 10:15 |
Isofol meddelar att en post hoc-analys per protokoll av AGENT-studien ger ytter…
|
Swedish | 79.0 KB | ||
| 2024-06-12 13:15 |
Isofols Chief Financial Officer lämnar bolaget
|
Swedish | 61.3 KB | ||
| 2024-06-12 13:15 |
Isofol's Chief Financial Officer to leave the company
|
English | 81.8 KB | ||
| 2024-05-24 13:55 |
Isofol and Charité sign collaboration agreement on further clinical development…
|
English | 71.3 KB | ||
| 2024-05-24 13:55 |
Isofol och Charité har tecknat ett samarbetsavtal om vidare klinisk utveckling …
|
Swedish | 75.3 KB | ||
| 2024-05-08 15:00 |
Kommuniké från årsstämma i Isofol Medical AB (publ) den 8 maj 2024
|
Swedish | 86.7 KB | ||
| 2024-05-08 15:00 |
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8,…
|
English | 87.1 KB | ||
| 2024-05-08 08:00 | Swedish | 675.7 KB | |||
| 2024-05-08 08:00 | Swedish | 675.7 KB | |||
| 2024-04-16 16:50 | Swedish | 10.5 MB | |||
| 2024-04-05 11:00 |
Kallelse till årsstämma den 8 maj 2024 i Isofol Medical AB (publ)
|
Swedish | 120.9 KB | ||
| 2024-04-05 11:00 |
Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medic…
|
English | 60.6 KB |
Automate Your Workflow. Get a real-time feed of all Isofol Medical filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Isofol Medical
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Isofol Medical via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-11 | Magnus Hurst | Other | Buy | 35,000 | 24,150.00 SEK |
| 2022-09-12 | AB Windar | Other | Buy | 500,000 | 305,000.00 SEK |
| 2021-12-09 | Tony Gustavsson | Other | Sell | 58,767 | 858.00 SEK |
| 2021-12-09 | Tony Gustavsson | Other | Sell | 58,767 | 152.79 SEK |
| 2021-06-14 | HealthCom GmbH | Other | Buy | 233,336 | 1,493,350.40 SEK |
| 2021-06-10 | Gustaf Albèrt | Other | Other | 15,153 | 96,979.20 SEK |
| 2020-11-23 | Tony Gustavsson | Other | Buy | 58,767 | 43,487.58 SEK |
| 2020-11-23 | Tony Gustavsson | Other | Buy | 58,767 | 29,971.17 SEK |
| 2020-11-16 | Sven Eriksson | Other | Sell | 58,767 | 43,487.58 SEK |
| 2020-11-16 | Sven Eriksson | Other | Sell | 58,767 | 29,971.17 SEK |
Peer Companies
